Composite Tissue Allotransplantation
Composite Tissue Allotransplantation - Related Videos
10:31
Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
0 Views •
Cited by 5 •
2017
Currently any kind of vascularized composite allotransplantation depends on long-term-immunosuppression, difficult to support for non-life-critical indications. We present a new porcine tibial VCA model that can be used to study bone VCA and demonstrate the use of surgical angiogenesis to maintain bone viability without the need of long-term immune-modulation.
09:14
Surgical Approach to Full Soft Tissue Face Allograft Procurement for Vascularized Composite Allotransplantation
0 Views •
2025
This protocol details the surgical technique used to harvest and prepare a full-face allograft for transplantation in patients with severe facial disfigurements, focusing primarily on soft tissue procurement with limited bony harvest restricted to the nasal framework.
06:53
Heterotopic Hindlimb-to-Neck Transplantation in the Mouse: A Supermicrosurgical Model of Vascularized Composite Allotransplantation
0 Views •
2026
We present a reproducible mouse model of heterotopic hindlimb-to-neck vascularized composite allotransplantation. This supermicrosurgical protocol, involving 0.3-0.5 mm vessel anastomoses, integrates nylon filament guidance and venous cuffing. It provides a reliable platform for translational studies on tolerance, ischemia-reperfusion injury, and immunological mechanisms in vascularized composite allotransplantation.
08:11
Vascularized Composite Upper Limb Allograft Harvesting for Proximal Arm Allotransplantation
0 Views •
2025
Here, the protocol explains step-by-step the technique of harvesting an upper arm allograft at the trans humeral or gleno-humeral level during an arm allotransplantation.
09:09
A Modified Heterotopic Swine Hind Limb Transplant Model for Translational Vascularized Composite Allotransplantation (VCA) Research
0 Views •
Cited by 34 •
2013
Vascularized Composite Allotransplantations (VCA) have become a clinical reality. However, broad clinical application of VCA is limited by chronic multi-drug immunosuppression. The authors present a reliable and reproducible large animal model to translate novel immunomodulatory strategies that can minimize or potentially eliminate the need of immunosuppression in VCA.
FAQs
Rejection begins when the recipient’s immune system identifies genetically different donor cells as foreign through their donor antigens. Two major pathways can contribute: cellular responses directed by immune cells and antibody-mediated responses involving antibodies against graft targets. Because a composite graft contains several tissue types, immune recognition remains an important determinant of graft survival and requires ongoing clinical attention.
Immunosuppressive therapy limits the recipient’s immune attack against donor tissues, helping preserve the graft after transplantation. Its use reflects the central balance in this approach: suppressing rejection strongly enough to support graft survival while avoiding excessive impairment of protective immunity. That balance is especially important because immunosuppression increases concern about infection and requires careful monitoring.
Immune tolerance refers to strategies that may allow the recipient to accept donor tissues with less dependence on long-term immunosuppression. This goal matters because reducing immunosuppressive exposure could lessen infectious risk while maintaining graft survival. The topic therefore connects transplantation immunology with infection control: immune activity must be moderated without compromising the recipient’s ability to resist infection.
This approach is used in selected cases of severe tissue loss, particularly when a limb, face, or other complex anatomical region has been extensively damaged. Consideration depends on the need to restore multiple components together rather than replace a single tissue alone. Its potential value lies in rebuilding anatomy in a way that can support meaningful physical function and quality of life.
A graft may include skin, muscle, bone, nerves, and blood vessels, with the specific combination determined by the anatomy and function that need restoration. These tissues are transplanted together as part of a complex anatomical reconstruction. Their inclusion allows the procedure to address structural and functional loss simultaneously, rather than focusing on only one damaged tissue type.
In appropriately selected recipients, transplantation can improve physical function and quality of life after severe limb, face, or other tissue loss. These outcomes extend beyond replacing tissue volume because the goal is restoration of complex anatomy and associated function. Achieving that benefit depends on maintaining graft survival while managing rejection and the infectious risks associated with immunosuppressive therapy.
Ongoing research focuses on immune-tolerance strategies that could preserve graft survival while reducing reliance on long-term immunosuppression. This direction addresses a central limitation of current care: the need to control cellular and antibody-mediated rejection while limiting infection risk. Safer approaches would aim to maintain the functional and quality-of-life benefits of transplantation with less long-term immune suppression.